Related Experiment Video

Updated: May 11, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Adoption of medication therapy management programs in Minnesota: 2006-11

Steven Larson1, Sara Drake, Lowell Anderson

  • 1College of Pharmacy, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA. lars1904@umn.edu

Journal of the American Pharmacists Association : Japha
|May 24, 2013
PubMed
Abstract

Insights

The Minnesota Department of Human Services (DHS) medication therapy management (MTM) program saw increasing adoption by pharmacists and patients from 2006-2011. Further recruitment strategies are recommended to expand patient reach.

Area of Science:

  • Health Services Research
  • Pharmaceutical Policy
  • Public Health Interventions

Background:

  • The Minnesota Department of Human Services (DHS) established a Medication Therapy Management (MTM) program to improve patient outcomes.
  • Understanding the program's adoption rate is crucial for assessing its effectiveness and identifying areas for growth.

Purpose of the Study:

  • To evaluate the uptake and utilization of the Minnesota DHS MTM program by both patients and pharmacists.
  • To analyze trends in program participation and service delivery over a defined period.

Main Methods:

  • A descriptive, nonexperimental study design was employed.
  • Data from the Minnesota DHS MTM program between 2006 and 2011 were analyzed.
  • Key metrics included annual claims, provider numbers, compensation, claim locations, and the percentage of eligible patients served.

Main Results:

  • In 2011, 76 pharmacists provided services for 2,427 claims, receiving $210,716 in compensation.
  • The program demonstrated consistent year-over-year growth in claims, participating pharmacists, and compensated amounts from 2006 to 2011.
  • An estimated 5.7% to 7.6% of eligible patients received MTM services in 2011, indicating potential for expansion.

Conclusions:

  • The Minnesota DHS MTM program shows promising initial success with a continued upward trend in utilization.
  • The relatively low percentage of eligible patients served suggests a need for enhanced patient and pharmacist recruitment strategies.
  • Further development of outreach and engagement tactics is recommended to maximize program impact.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).